Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis

Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are the most commonly used diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the immunoglobulin (Ig) M (RF) or IgG (ACPA) isotype. Other subtypes of both antibodies-particularly IgA isotypes...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in Immunology Vol. 9; p. 876
Main Authors Sieghart, Daniela, Platzer, Alexander, Studenic, Paul, Alasti, Farideh, Grundhuber, Maresa, Swiniarski, Sascha, Horn, Thomas, Haslacher, Helmuth, Blüml, Stephan, Smolen, Josef, Steiner, Günter
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media SA 24.04.2018
Frontiers Media S.A
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2018.00876

Cover

Abstract Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are the most commonly used diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the immunoglobulin (Ig) M (RF) or IgG (ACPA) isotype. Other subtypes of both antibodies-particularly IgA isotypes and other autoantibodies-such as RA33 antibodies-have been repeatedly reported but their diagnostic value has still not been fully elucidated. Here, we investigated the prevalence of IgA, IgG, and IgM subtypes of RF, ACPA, and RA33 antibodies in patients with RA. To determine the diagnostic specificity and sensitivity sera from 290 RA patients (165 early and 125 established disease), 261 disease controls and 100 healthy subjects were tested for the presence of IgA, IgG, and IgM isotypes of RF, ACPA, and RA33 by EliA™ platform (Phadia AB, Uppsala, Sweden). The most specific antibodies were IgG-ACPA, IgA-ACPA, and IgG-RF showing specificities >98%, closely followed by IgG- and IgA-RA33 while IgM subtypes were somewhat less specific, ranging from 95.8% (RA33) to 90% (RF). On the other hand, IgM-RF was the most sensitive subtype (65%) followed by IgG-ACPA (59.5%) and IgA-RF (50.7%). Other subtypes were less sensitive ranging from 35 (IgA-ACPA) to 6% (IgA-RA33). RA33 antibodies as well as IgA-RF and IgA-ACPA were found to increase the diagnostic sensitivity of serological testing since they were detected also in seronegative patients reducing their number from 109 to 85. Moreover, analyzing IgM-RF by EliA™ proved more sensitive than measuring RF by nephelometry and further reduced the number of seronegative patients to 76 individuals. Importantly, among antibody positive individuals, RA patients were found having significantly more antibodies (≥3) than disease controls which generally showed one or two antibody species. Thus, increasing the number of autoantibodies in serological routine testing provides valuable additional information allowing to better distinguish between RA and other rheumatic disorders, also in patients not showing antibodies in current routine diagnostics. In conclusion, testing for multiple autoantibody specificities increases the diagnostic power of autoimmune diagnostics and could further support physicians in clinical decision-making.
AbstractList Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are the most commonly used diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the immunoglobulin (Ig) M (RF) or IgG (ACPA) isotype. Other subtypes of both antibodies-particularly IgA isotypes and other autoantibodies-such as RA33 antibodies-have been repeatedly reported but their diagnostic value has still not been fully elucidated. Here, we investigated the prevalence of IgA, IgG, and IgM subtypes of RF, ACPA, and RA33 antibodies in patients with RA. To determine the diagnostic specificity and sensitivity sera from 290 RA patients (165 early and 125 established disease), 261 disease controls and 100 healthy subjects were tested for the presence of IgA, IgG, and IgM isotypes of RF, ACPA, and RA33 by EliA™ platform (Phadia AB, Uppsala, Sweden). The most specific antibodies were IgG-ACPA, IgA-ACPA, and IgG-RF showing specificities >98%, closely followed by IgG- and IgA-RA33 while IgM subtypes were somewhat less specific, ranging from 95.8% (RA33) to 90% (RF). On the other hand, IgM-RF was the most sensitive subtype (65%) followed by IgG-ACPA (59.5%) and IgA-RF (50.7%). Other subtypes were less sensitive ranging from 35 (IgA-ACPA) to 6% (IgA-RA33). RA33 antibodies as well as IgA-RF and IgA-ACPA were found to increase the diagnostic sensitivity of serological testing since they were detected also in seronegative patients reducing their number from 109 to 85. Moreover, analyzing IgM-RF by EliA™ proved more sensitive than measuring RF by nephelometry and further reduced the number of seronegative patients to 76 individuals. Importantly, among antibody positive individuals, RA patients were found having significantly more antibodies (≥3) than disease controls which generally showed one or two antibody species. Thus, increasing the number of autoantibodies in serological routine testing provides valuable additional information allowing to better distinguish between RA and other rheumatic disorders, also in patients not showing antibodies in current routine diagnostics. In conclusion, testing for multiple autoantibody specificities increases the diagnostic power of autoimmune diagnostics and could further support physicians in clinical decision-making.Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are the most commonly used diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the immunoglobulin (Ig) M (RF) or IgG (ACPA) isotype. Other subtypes of both antibodies-particularly IgA isotypes and other autoantibodies-such as RA33 antibodies-have been repeatedly reported but their diagnostic value has still not been fully elucidated. Here, we investigated the prevalence of IgA, IgG, and IgM subtypes of RF, ACPA, and RA33 antibodies in patients with RA. To determine the diagnostic specificity and sensitivity sera from 290 RA patients (165 early and 125 established disease), 261 disease controls and 100 healthy subjects were tested for the presence of IgA, IgG, and IgM isotypes of RF, ACPA, and RA33 by EliA™ platform (Phadia AB, Uppsala, Sweden). The most specific antibodies were IgG-ACPA, IgA-ACPA, and IgG-RF showing specificities >98%, closely followed by IgG- and IgA-RA33 while IgM subtypes were somewhat less specific, ranging from 95.8% (RA33) to 90% (RF). On the other hand, IgM-RF was the most sensitive subtype (65%) followed by IgG-ACPA (59.5%) and IgA-RF (50.7%). Other subtypes were less sensitive ranging from 35 (IgA-ACPA) to 6% (IgA-RA33). RA33 antibodies as well as IgA-RF and IgA-ACPA were found to increase the diagnostic sensitivity of serological testing since they were detected also in seronegative patients reducing their number from 109 to 85. Moreover, analyzing IgM-RF by EliA™ proved more sensitive than measuring RF by nephelometry and further reduced the number of seronegative patients to 76 individuals. Importantly, among antibody positive individuals, RA patients were found having significantly more antibodies (≥3) than disease controls which generally showed one or two antibody species. Thus, increasing the number of autoantibodies in serological routine testing provides valuable additional information allowing to better distinguish between RA and other rheumatic disorders, also in patients not showing antibodies in current routine diagnostics. In conclusion, testing for multiple autoantibody specificities increases the diagnostic power of autoimmune diagnostics and could further support physicians in clinical decision-making.
Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are the most commonly used diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the immunoglobulin (Ig) M (RF) or IgG (ACPA) isotype. Other subtypes of both antibodies—particularly IgA isotypes and other autoantibodies—such as RA33 antibodies—have been repeatedly reported but their diagnostic value has still not been fully elucidated. Here, we investigated the prevalence of IgA, IgG, and IgM subtypes of RF, ACPA, and RA33 antibodies in patients with RA. To determine the diagnostic specificity and sensitivity sera from 290 RA patients (165 early and 125 established disease), 261 disease controls and 100 healthy subjects were tested for the presence of IgA, IgG, and IgM isotypes of RF, ACPA, and RA33 by EliA™ platform (Phadia AB, Uppsala, Sweden). The most specific antibodies were IgG-ACPA, IgA-ACPA, and IgG-RF showing specificities >98%, closely followed by IgG- and IgA-RA33 while IgM subtypes were somewhat less specific, ranging from 95.8% (RA33) to 90% (RF). On the other hand, IgM-RF was the most sensitive subtype (65%) followed by IgG-ACPA (59.5%) and IgA-RF (50.7%). Other subtypes were less sensitive ranging from 35 (IgA-ACPA) to 6% (IgA-RA33). RA33 antibodies as well as IgA-RF and IgA-ACPA were found to increase the diagnostic sensitivity of serological testing since they were detected also in seronegative patients reducing their number from 109 to 85. Moreover, analyzing IgM-RF by EliA™ proved more sensitive than measuring RF by nephelometry and further reduced the number of seronegative patients to 76 individuals. Importantly, among antibody positive individuals, RA patients were found having significantly more antibodies (≥3) than disease controls which generally showed one or two antibody species. Thus, increasing the number of autoantibodies in serological routine testing provides valuable additional information allowing to better distinguish between RA and other rheumatic disorders, also in patients not showing antibodies in current routine diagnostics. In conclusion, testing for multiple autoantibody specificities increases the diagnostic power of autoimmune diagnostics and could further support physicians in clinical decision-making.
Author Sascha; Horn
Sieghart
Helmuth; Blueml
Alexander; Studenic
Josef; Steiner
Daniela; Platzer
Maresa; Swiniarski
Paul; Alasti
Thomas; Haslacher
Stephan; Smolen
Farideh; Grundhuber
Guenter
AuthorAffiliation 2 Thermo Fisher Scientific, Phadia GmbH , Freiburg , Germany
1 Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna , Austria
3 Thermo Fisher Scientific, Phadia Austria GmbH , Vienna , Austria
4 Department of Laboratory Medicine, Medical University of Vienna , Vienna , Austria
AuthorAffiliation_xml – name: 4 Department of Laboratory Medicine, Medical University of Vienna , Vienna , Austria
– name: 1 Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna , Austria
– name: 2 Thermo Fisher Scientific, Phadia GmbH , Freiburg , Germany
– name: 3 Thermo Fisher Scientific, Phadia Austria GmbH , Vienna , Austria
Author_xml – sequence: 1
  givenname: Daniela
  surname: Sieghart
  fullname: Sieghart, Daniela
– sequence: 2
  givenname: Alexander
  surname: Platzer
  fullname: Platzer, Alexander
– sequence: 3
  givenname: Paul
  surname: Studenic
  fullname: Studenic, Paul
– sequence: 4
  givenname: Farideh
  surname: Alasti
  fullname: Alasti, Farideh
– sequence: 5
  givenname: Maresa
  surname: Grundhuber
  fullname: Grundhuber, Maresa
– sequence: 6
  givenname: Sascha
  surname: Swiniarski
  fullname: Swiniarski, Sascha
– sequence: 7
  givenname: Thomas
  surname: Horn
  fullname: Horn, Thomas
– sequence: 8
  givenname: Helmuth
  surname: Haslacher
  fullname: Haslacher, Helmuth
– sequence: 9
  givenname: Stephan
  surname: Blüml
  fullname: Blüml, Stephan
– sequence: 10
  givenname: Josef
  surname: Smolen
  fullname: Smolen, Josef
– sequence: 11
  givenname: Günter
  surname: Steiner
  fullname: Steiner, Günter
BackLink https://cir.nii.ac.jp/crid/1871147691292693120$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/29740454$$D View this record in MEDLINE/PubMed
BookMark eNp9UktvEzEQtlARLaF3TmgPHLgkjN_rC1JUXpEqIVE4W95db-KyawfbWyn_Hm_SopYDPtij8XwPab6X6MwHbxF6jWFFaa3e924cpxUBXK8AaimeoQssBFtSQtjZo_ocXaZ0C-UwRSnlL9A5UZIB4-wC_fpos42j8ya74KvQV-spB-Oza0J3qDYp5MPepmrj22hNKlXe2erG-uSyu3P5MENubAydM1sfUnZtqpyvvu_sNJocXFetY97FMp1eoee9GZK9vH8X6OfnTz-uvi6vv33ZXK2vly3nMi8lxtATRoQkllPAAMLWvcK0abghBCxA00sCvKulAdHhvmFgJKEcGlIrRRdoc-LtgrnV--hGEw86GKePjRC32sRidLCaWw6yrqXCnWSESMMYE50BTBUozGTh-nDi2k_NaLvW-hzN8IT06Y93O70Nd5orUghmM-_uCWL4PdmU9ehSa4fBeBumpAlQIWtJiv8FevNY66_Iw7bKgDgNtDGkFG2vW5ePiyvSbtAY9JwMfUyGnpOhj8koQPgH-MD9H8jbE8Q7V2TmG9dlNUwKhYkiQlFcvP8BgnvGjw
CitedBy_id crossref_primary_10_3389_fimmu_2022_1096866
crossref_primary_10_1016_j_chest_2020_04_075
crossref_primary_10_1136_rmdopen_2022_002705
crossref_primary_10_1016_j_plabm_2024_e00420
crossref_primary_10_3390_ijms24043321
crossref_primary_10_1515_cclm_2022_0411
crossref_primary_10_3390_molecules27041452
crossref_primary_10_1515_cclm_2023_0109
crossref_primary_10_1016_j_clinbiochem_2020_05_019
crossref_primary_10_1080_10408363_2020_1775545
crossref_primary_10_1080_14737159_2023_2247986
crossref_primary_10_1093_rheumatology_keae297
crossref_primary_10_1136_ard_2023_223901
crossref_primary_10_1136_rmdopen_2022_002817
crossref_primary_10_1371_journal_pone_0290793
crossref_primary_10_1080_03009742_2020_1713395
crossref_primary_10_1515_cclm_2022_0244
crossref_primary_10_47360_1995_4484_2023_276_291
crossref_primary_10_23736_S1825_859X_21_00114_6
crossref_primary_10_1038_s41598_019_56279_0
crossref_primary_10_1186_s13075_020_02191_2
crossref_primary_10_1007_s10787_022_01035_6
crossref_primary_10_1093_jalm_jfab132
crossref_primary_10_1007_s10067_021_05814_4
crossref_primary_10_3389_fimmu_2021_651049
crossref_primary_10_3390_ijms25126460
crossref_primary_10_1007_s12026_024_09500_w
crossref_primary_10_1371_journal_pone_0265687
crossref_primary_10_15212_AMM_2022_0039
crossref_primary_10_1136_rmdopen_2023_003851
crossref_primary_10_47836_mjmhs_19_1_14
crossref_primary_10_1186_s13075_020_02252_6
crossref_primary_10_1007_s12026_023_09402_3
crossref_primary_10_3899_jrheum_2023_0907
crossref_primary_10_3389_fimmu_2023_1116435
crossref_primary_10_3389_fopht_2023_1106419
crossref_primary_10_3390_cells10113017
crossref_primary_10_3899_jrheum_220881
crossref_primary_10_1016_j_bios_2019_111642
crossref_primary_10_3389_fimmu_2020_01108
crossref_primary_10_1002_art_42463
crossref_primary_10_1111_iji_12643
crossref_primary_10_3389_fmed_2023_1129939
crossref_primary_10_1111_jcpe_13277
crossref_primary_10_3390_cancers13040591
crossref_primary_10_1111_joim_13058
crossref_primary_10_1136_rmdopen_2022_002511
crossref_primary_10_1136_rmdopen_2021_002099
crossref_primary_10_3389_fmed_2021_802934
crossref_primary_10_1097_BOR_0000000000001006
crossref_primary_10_1136_bmjopen_2020_048409
crossref_primary_10_17650_1818_8338_2022_16_3_K669
Cites_doi 10.1016/j.cca.2014.05.019
10.1186/s13075-016-0940-2
10.1093/rheumatology/keu215
10.1002/art.11223
10.1002/art.39595
10.1155/2013/726598
10.1136/ard.2008.100677
10.1093/rheumatology/keg184
10.1186/1546-0096-11-31
10.1093/rheumatology/32.3.199
10.1136/ard.2010.138461
10.1186/s13075-017-1329-6
10.1186/1471-2105-12-77
10.1515/cclm-2017-0988
10.1038/nrrheum.2016.151
10.1016/j.autrev.2009.11.017
10.1007/s00393-016-0134-y
10.1136/annrheumdis-2016-209297
10.1002/art.39299
10.1038/nri.2016.124
10.1038/nrrheum.2017.15
10.1136/ard.2005.035691
ContentType Journal Article
Copyright Copyright © 2018 Sieghart, Platzer, Studenic, Alasti, Grundhuber, Swiniarski, Horn, Haslacher, Blüml, Smolen and Steiner. 2018 Sieghart, Platzer, Studenic, Alasti, Grundhuber, Swiniarski, Horn, Haslacher, Blüml, Smolen and Steiner
Copyright_xml – notice: Copyright © 2018 Sieghart, Platzer, Studenic, Alasti, Grundhuber, Swiniarski, Horn, Haslacher, Blüml, Smolen and Steiner. 2018 Sieghart, Platzer, Studenic, Alasti, Grundhuber, Swiniarski, Horn, Haslacher, Blüml, Smolen and Steiner
DBID RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2018.00876
DatabaseName CiNii Complete
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_5e50788791d74227a4446da013909147
PMC5929149
29740454
10_3389_fimmu_2018_00876
Genre Evaluation Studies
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Innovative Medicines Initiative Joint Undertaking
  grantid: 777357, 115142
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
RYH
AAYXX
ACXDI
CITATION
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c557t-7110f242672e5301006e8f913bb5a220e00bf7205d87a06d1fb40a72350b28993
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:25:24 EDT 2025
Thu Aug 21 18:16:30 EDT 2025
Thu Sep 04 18:35:32 EDT 2025
Thu Apr 03 07:26:18 EDT 2025
Tue Jul 01 01:35:21 EDT 2025
Thu Apr 24 22:56:03 EDT 2025
Mon Aug 18 12:15:07 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords anti-citrullinated protein antibodies
autoantibodies
rheumatoid arthritis
RA33 antibodies
rheumatoid factor
immunoglobulin isotypes
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c557t-7110f242672e5301006e8f913bb5a220e00bf7205d87a06d1fb40a72350b28993
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
Specialty section: This article was submitted to Inflammation, a section of the journal Frontiers in Immunology
These authors have contributed equally to this work.
Edited by: Philippe Saas, INSERM UMR1098 Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, France
Reviewed by: Yasser El-Sherbiny, University of Leeds, United Kingdom; Willem Falkenburg, Sanquin, Netherlands
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2018.00876
PMID 29740454
PQID 2036787272
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_5e50788791d74227a4446da013909147
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5929149
proquest_miscellaneous_2036787272
pubmed_primary_29740454
crossref_citationtrail_10_3389_fimmu_2018_00876
crossref_primary_10_3389_fimmu_2018_00876
nii_cinii_1871147691292693120
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-04-24
PublicationDateYYYYMMDD 2018-04-24
PublicationDate_xml – month: 04
  year: 2018
  text: 2018-04-24
  day: 24
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in Immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2018
Publisher Frontiers Media SA
Frontiers Media S.A
Publisher_xml – name: Frontiers Media SA
– name: Frontiers Media S.A
References Malmstrom (B1) 2017; 17
Trouw (B20) 2016; 12
Nell-Duxneuner (B12) 2010; 69
Aletaha (B2) 2010; 69
Rantapaa-Dahlqvist (B3) 2003; 48
Ingegnoli (B17) 2013; 35
Falkenburg (B6) 2015; 67
Lee (B19) 2017; 76
Trouw (B23) 2017; 13
Cabrera-Villalba (B24) 2017; 19
Hajian-Tilaki (B15) 2013; 4
Falkenburg (B18) 2018
Conrad (B5) 2010; 9
Robin (B16) 2011; 17
Infantino (B8) 2014; 436
Bas (B4) 2003; 42
Nell (B11) 2005; 64
Gottenberg (B22) 2016; 68
Gilliam (B7) 2013; 11
Ball (B14) 2014; 53
Figueiredo (B21) 2017; 76
Brink (B9) 2016; 18
Hassfeld (B10) 1993; 32
Yang (B13) 2016; 34
References_xml – volume: 436
  start-page: 237
  year: 2014
  ident: B8
  article-title: Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2014.05.019
– volume: 18
  start-page: 43
  year: 2016
  ident: B9
  article-title: Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis
  publication-title: Arthritis Res Ther
  doi: 10.1186/s13075-016-0940-2
– volume: 53
  start-page: 1835
  year: 2014
  ident: B14
  article-title: A study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keu215
– volume: 48
  start-page: 2741
  year: 2003
  ident: B3
  article-title: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.11223
– volume: 68
  start-page: 1346
  year: 2016
  ident: B22
  article-title: Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European Registry Analysis
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39595
– volume: 35
  start-page: 727
  year: 2013
  ident: B17
  article-title: Rheumatoid factors: clinical applications
  publication-title: Dis Markers
  doi: 10.1155/2013/726598
– volume: 69
  start-page: 169
  year: 2010
  ident: B12
  article-title: Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.100677
– volume: 42
  start-page: 677
  year: 2003
  ident: B4
  article-title: Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keg184
– volume: 11
  start-page: 31
  year: 2013
  ident: B7
  article-title: Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis
  publication-title: Pediatr Rheumatol Online J
  doi: 10.1186/1546-0096-11-31
– volume: 32
  start-page: 199
  year: 1993
  ident: B10
  article-title: Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis
  publication-title: Br J Rheumatol
  doi: 10.1093/rheumatology/32.3.199
– volume: 69
  start-page: 1580
  year: 2010
  ident: B2
  article-title: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.138461
– volume: 19
  start-page: 141
  year: 2017
  ident: B24
  article-title: Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis
  publication-title: Arthritis Res Ther
  doi: 10.1186/s13075-017-1329-6
– volume: 17
  start-page: 77
  year: 2011
  ident: B16
  article-title: pROC: an open-source package for R and S+ to analyze and compare ROC curves
  publication-title: BMC Bioinformatics
  doi: 10.1186/1471-2105-12-77
– year: 2018
  ident: B18
  article-title: Clinically relevant discrepancies between different rheumatoid factor assays
  publication-title: Clin Chem Lab Med
  doi: 10.1515/cclm-2017-0988
– volume: 12
  start-page: 566
  year: 2016
  ident: B20
  article-title: Rheumatoid arthritis: autoantibody testing to predict response to therapy in RA
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2016.151
– volume: 9
  start-page: 431
  year: 2010
  ident: B5
  article-title: Profiling of rheumatoid arthritis associated autoantibodies
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2009.11.017
– volume: 76
  start-page: 535
  year: 2017
  ident: B19
  article-title: Diagnostic accuracy of anti-Sa and anti-RA33 antibodies in rheumatoid arthritis: a meta-analysis
  publication-title: Z Rheumatol
  doi: 10.1007/s00393-016-0134-y
– volume: 76
  start-page: 399
  year: 2017
  ident: B21
  article-title: Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2016-209297
– volume: 34
  start-page: 539
  year: 2016
  ident: B13
  article-title: Diagnostic accuracy of anti-RA33 antibody for rheumatoid arthritis: systematic review and meta-analysis
  publication-title: Clin Exp Rheumatol
– volume: 4
  start-page: 627
  year: 2013
  ident: B15
  article-title: Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation
  publication-title: Caspian J Intern Med
– volume: 67
  start-page: 3124
  year: 2015
  ident: B6
  article-title: IgG subclass specificity discriminates restricted IgM rheumatoid factor responses from more mature anti-citrullinated protein antibody-associated or Isotype-switched IgA responses
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39299
– volume: 17
  start-page: 60
  year: 2017
  ident: B1
  article-title: The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri.2016.124
– volume: 13
  start-page: 331
  year: 2017
  ident: B23
  article-title: Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2017.15
– volume: 64
  start-page: 1731
  year: 2005
  ident: B11
  article-title: Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2005.035691
SSID ssj0000493335
Score 2.4094567
Snippet Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are the most commonly used diagnostic markers of rheumatoid arthritis (RA). These...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
nii
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 876
SubjectTerms Aged
Anti-Citrullinated Protein Antibodies
Anti-Citrullinated Protein Antibodies - blood
Anti-Citrullinated Protein Antibodies - immunology
Antibody Specificity
Antibody Specificity - immunology
Arthritis, Rheumatoid
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - immunology
autoantibodies
Case-Control Studies
Diagnostic Tests, Routine
Diagnostic Tests, Routine - methods
Female
Healthy Volunteers
Humans
immunoglobulin isotypes
Immunoglobulin Isotypes - blood
Immunoglobulin Isotypes - immunology
Immunologic diseases. Allergy
Immunology
Male
Middle Aged
RA33 antibodies
RC581-607
rheumatoid arthritis
rheumatoid factor
Rheumatoid Factor - blood
Rheumatoid Factor - immunology
Sensitivity and Specificity
Serologic Tests
Serologic Tests - methods
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqSki9IB4FAhQZqRcO0Tp-xMmxPKqCRA-FSr1ZdmxrA22C2M2h_54Ze3e1i6py4bKK8tB6Z8ae71tPviHk2FcO0jx4oGPBl9JJXloPLEVbXovIeGhT_5Sv5_XZpfxypa62Wn1hTViWB86Gm6kAiAVmQlt5YHFcWwkExltELpDqZHqPnLVsi0z9yLhXCKHyviSwsHYW-5ubCUu5sHayQYmRrTyU5Pohuwx9fxfS_LtgcisDnT4iD1fQkZ7kIT8me2F4Qh7kZpK3T8nPj-vKFrQ1HSM9mZYjGK53o7-lnxcj_t26oLAiYCE6HAH2o9-wgD13kMBHYOkYfa6-Q_1m2g_0Yh4mgLVj7_Gr50kE6ZBcnn76_uGsXLVSKDul9LLUkOUjZmPNg4I5DXMtNLGthHPKcs4CYy5qzpRvtGW1r6KTzGouFHNIycQzsj-MQ3hBaFN1SDp8jLqTtoXrQQsHKEyyxqraFWS2NqzpVjrj2O7i2gDfQFeY5AqDrjDJFQV5t3niV9bYuOfe9-irzX2ojp1OQMyYVcyYf8VMQY7A0zA6_KyAMsK5ugXkw-tWVJwV5O06BgzMNtxCsUMYp4XBbVtY4rjmBXmeY2IzFA7UDAUNC6J3omVnrLtXhn6eFL0VgFSgqi__x497RQ7QXLjjxeVrsr_8PYUjAE5L9ybNkT8EmxEB
  priority: 102
  providerName: Directory of Open Access Journals
Title Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis
URI https://cir.nii.ac.jp/crid/1871147691292693120
https://www.ncbi.nlm.nih.gov/pubmed/29740454
https://www.proquest.com/docview/2036787272
https://pubmed.ncbi.nlm.nih.gov/PMC5929149
https://doaj.org/article/5e50788791d74227a4446da013909147
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagCIkLojwDtDISFw6hjh_x5oBQaSkFqRyAlfZm2bHTTWlj2N1I7L9nJsluWbSCSxQ5tmLNeDzfF09mCHnpMwduHjRQsuBT6SRPrQeWoi3PRcV4KLr6KWef89Ox_DRRk-vfowcBzrdSO6wnNZ5dvv71c_kWDP4NMk7wtwdVfXXVYpQWhkWCdd8kt8Av5UjFzgawf9FjYSGE6s8qtw7c8E1dCn_wOE1db0OffwdR_uGVTu6RuwOcpIe9_nfJjQt7n9zuC0wuH5Dvx6toF5Q_jRU9bBcRhFm76Jf04zziJ9g5hV0Cg9PhDvAg_YpB7X1VCRwC20n0fUQe5nSmdUO_TEMLUDfWHl897RIjPSTjk_ffjk7TobxCWiqlF6kGz1-hh9Y8KLBzsL8wqopMOKcs5yww5irNmfIjbVnus8pJZjUXijmkaeIR2WliE54QOspKJCK-qnQpbQHPgxYOkJlkI6tyl5CDlWBNOeQexxIYlwY4CKrCdKowqArTqSIhr9YjfvR5N_7R9x3qat0PM2Z3DXF2bgYDNCoA8oUdtci8lpxrK4EIe4sIGCCT1AnZA03D7PCaAY2EtrwANMTzQmScJeTFag0YsEA8VrFNiO3c4FEubHtc84Q87tfEeioc6BomOUyI3lgtG3PdfNLU0y7LtwLgCvT16X_m9YzcQUngAReXz8nOYtaGPcBJC7fffV-A64dJtt-Zwm8v7A6-
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Determination+of+Autoantibody+Isotypes+Increases+the+Sensitivity+of+Serodiagnostics+in+Rheumatoid+Arthritis&rft.jtitle=Frontiers+in+Immunology&rft.au=Sieghart&rft.au=Daniela%3B+Platzer&rft.au=Alexander%3B+Studenic&rft.au=Paul%3B+Alasti&rft.date=2018-04-24&rft.pub=Frontiers+Media+SA&rft.eissn=1664-3224&rft.volume=9&rft_id=info:doi/10.3389%2Ffimmu.2018.00876
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon